The idea of using liquid biopsy in the field of oncology is relatively new. Its
significant advancement and revolutionized diagnosis and therapy monitoring in cancer
research is strengthening the field of precision medicine. Liquid biopsy is a noninvasive
method of isolation and detection of circulating tumor cells, circulating tumor
DNA and exosome depict the exact picture of early stage cancer genomics and
proteomics. The techniques like digital PCR, CAPPSEQ, BEAMing and next
generation sequencing contributed to utilize liquid biopsy in clinical settings. It can
facilitate cancer prognosis and early stage detection before metastasis. Importantly, it
can help in finding responders and non-responders, devising treatement plan and
screening of new drugs. In this chapter, the clinical application of liquid biopsy in solid
tumor management with focus on Hepatocellular Carcinoma (HCC) is discussed.
Besides the advancement in diagnostics and treatment of HCC, the prognosis is still
poor with a high rate of mortality. Liquid biopsy has the potential for better diagnosis
and monitoring of HCC in patients. We have also summarized different advanced
diagnostic techniques for the isolation and enrichment of circulating tumor cells,
circulating tumor DNA and exosome. Moreover, the limitation of the use of liquid
biopsy in the healthcare system is also the point of discussion.
Keywords: Circulating tumor cells, Circulating tumor DNA, Diagnosis,
Exosomes, Hepatocellular carcinoma, Liquid biopsy, Prognosis.
